Zimmer Biomet Holdings, Inc. Q2 FY26 Earnings Analysis

- U.S. business grew 3.2% in Q1 2026; international grew 2.5%. - Overall organic constant currency revenue growth guidance for 2026 maintained at 1% to 3%. - Growth expected to be roughly consistent throughout 2026. - Paragon 28 acquisition to contribute ~100 basis points to reported sales growth in 2026. - Technology and data, bone cement, surgical business grew nearly 12% in Q1 driving growth. - Knee market: U.S. knees grew 2.2% with strong partial knee sales; hips grew 5% in the U.S. - International markets expected mid-single digit growth in second half of 2026. - Monogram robotic system launch anticipated in early 2027 expected to drive future growth. - Sales force transformation enhancing productivity and specialty focus to support growth. - Pricing erosion expected up to 100 basis points in 2026, consistent with guidance. - Free cash flow growth guidance raised to 9%-11% for 2026.

- Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45. - Free cash flow growth guidance increased to 9% to 11%, from the previous 8% to 10%. - Operating margins for 2026 are expected to be slightly down, better than previously anticipated, with a modest decline of less than 50 basis points from 2025, despite investments and acquisition dilution. - Q2 2026 operating margins are expected to be down roughly 200 basis points from Q2 2025; Q3 expected to improve sequentially by about 50 basis points. - Pricing pressures anticipated with a full-year assumption of up to 100 basis points of price erosion. - The company remains confident in the direction given strong Q1 results, ongoing go-to-market transformations, and robust innovation pipeline, with updates expected in the August call.

- Zimmer Biomet is investing heavily in innovation and go-to-market transformation, including technology launches like Monogram (expected early 2027) and expansion of the sales force with over 200 new reps specifically for Monogram. - The company is expanding its manufacturing footprint into lower-cost geographies to improve operational efficiency and margins. - There is a sizable investment focus on building clinical evidence, economic strategy, and new customer targeting strategies to drive adoption of new products. - Zimmer Biomet committed as the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund focusing on breakthrough technologies such as AI, data applications, and cartilage repair. - Hiring Dr. Jonathan [indiscernible] as Chief Science Technology and Medical Affairs Officer to lead strategy and innovation around AI-enabled robotics, software, smart implants, and connected technologies. - Investments support future-proofing the company and building a robust technology portfolio, including connected and robotic solutions (Monogram, ROSA, TMINI).

- There is no mention of any current or planned fundraising through new debt or equity in the provided transcript. - The company continues to assume up to $750 million of share repurchases remain unchanged, indicating share buybacks rather than issuance. - Interest expense, tax rate, and share count guidance remain stable, suggesting no new significant debt issuance planned. - Focus appears to be on operational excellence, innovation, and go-to-market transformation funded internally. - No discussion of new financing rounds, equity offerings, or debt raises was made during the Q&A or remarks.

The provided transcript does not explicitly mention current or expected order book or pending orders figures. However, relevant insights related to demand and sales momentum include: - International markets expect mid-single digit growth in the second half of 2026 after some disruptions and distributor changes (Page 9). - The U.S. market shows solid growth with a 4-4.5% durable market growth rate, though knees need acceleration and hips expected to improve (Page 12). - Technology sales, including robotics and new products like Monogram and ROSA, grew 30% in Q1 supporting future order potential (Pages 8-9). - Sales force transformation progressing, with improved productivity and increasing dedicated reps, supporting stronger sales execution ahead (Pages 6-7). - No specific quantification of the order backlog or pending orders was disclosed during the call.